ADI-PEG 20 Depletes Arginine to Induce Antitumor Activity [Clinical Trials]
ADI-PEG 20 plus chemotherapy achieves partial responses in 7 of 9 patients with mesothelioma or NSCLC.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Mesothelioma | Non-Small Cell Lung Cancer